Unknown

Dataset Information

0

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.


ABSTRACT: While the addition of radiation to chemotherapy improves survival in patients with locally advanced pancreatic cancer, more effective therapies are urgently needed. Thus, we investigated the radiosensitizing efficacy of the novel drug combination of Wee1 and PARP1/2 inhibitors (AZD1775 and olaparib, respectively) in pancreatic cancer.Radiosensitization of AsPC-1 or MiaPaCa-2 human pancreatic cancer cells was assessed by clonogenic survival and tumor growth assays. Mechanistically, the effects of AZD1775, olaparib, and radiation on cell cycle, DNA damage (?H2AX), and homologous recombination repair (HRR) were determined.Treatment of AsPC-1 and MiaPaCa-2 cells with either AZD1775 or olaparib caused modest radiosensitization, whereas treatment with the combination significantly increased radiosensitization. Radiosensitization by the combination of AZD1775 and olaparib was associated with G2 checkpoint abrogation and persistent DNA damage. In addition, AZD1775 inhibited HRR activity and prevented radiation-induced Rad51 focus formation. Finally, in vivo, in MiaPaCa-2-derived xenografts, olaparib did not radiosensitize, whereas AZD1775 produced moderate, yet significant, radiosensitization (P < 0.05). Importantly, the combination of AZD1775 and olaparib produced highly significant radiosensitization (P < 0.0001) evidenced by a 13-day delay in tumor volume doubling (vs. radiation alone) and complete eradication of 20% of tumors.Taken together, these results demonstrate the efficacy of combined inhibition of Wee1 and PARP inhibitors for radiosensitizing pancreatic cancers and support the model that Wee1 inhibition sensitizes cells to PARP inhibitor-mediated radiosensitization through inhibition of HRR and abrogation of the G2 checkpoint, ultimately resulting in unrepaired, lethal DNA damage and radiosensitization. Clin Cancer Res; 20(19); 5085-96. ©2014 AACR.

SUBMITTER: Karnak D 

PROVIDER: S-EPMC4184968 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Karnak David D   Engelke Carl G CG   Parsels Leslie A LA   Kausar Tasneem T   Wei Dongping D   Robertson Jordan R JR   Marsh Katherine B KB   Davis Mary A MA   Zhao Lili L   Maybaum Jonathan J   Lawrence Theodore S TS   Morgan Meredith A MA  

Clinical cancer research : an official journal of the American Association for Cancer Research 20140812 19


<h4>Purpose</h4>While the addition of radiation to chemotherapy improves survival in patients with locally advanced pancreatic cancer, more effective therapies are urgently needed. Thus, we investigated the radiosensitizing efficacy of the novel drug combination of Wee1 and PARP1/2 inhibitors (AZD1775 and olaparib, respectively) in pancreatic cancer.<h4>Experimental design</h4>Radiosensitization of AsPC-1 or MiaPaCa-2 human pancreatic cancer cells was assessed by clonogenic survival and tumor gr  ...[more]

Similar Datasets

| S-EPMC3272262 | biostudies-other
| S-EPMC5805596 | biostudies-literature
| S-EPMC3819636 | biostudies-literature
| S-EPMC8345075 | biostudies-literature
| S-EPMC8014995 | biostudies-literature
| S-EPMC3478315 | biostudies-literature
| S-EPMC5528607 | biostudies-literature
| S-EPMC5915994 | biostudies-literature
| S-EPMC5056606 | biostudies-literature
| S-EPMC4657142 | biostudies-literature